Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
Public ClinicalTrials.gov record NCT00059826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma
Study identification
- NCT ID
- NCT00059826
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Interventions
- 5-fluorouracil Drug
- cisplatin Drug
- interferon-alfa-2b Biological
- radiation therapy Radiation
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2003
- Primary completion
- Jun 30, 2007
- Completion
- Jan 31, 2011
- Last update posted
- Dec 6, 2016
2003 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida Shands Cancer Center | Gainesville | Florida | 32610-0232 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| James Graham Brown Cancer Center at University of Louisville | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Fairview University Medical Center - University Campus | Minneapolis | Minnesota | 55455 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Presbyterian Hospital of Dallas | Dallas | Texas | 75231 | — |
| Baylor University Medical Center - Houston | Houston | Texas | 77030 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00059826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2016 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00059826 live on ClinicalTrials.gov.